Overview

Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer

Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
It has been accepted and proven that patients with unresectable lung cancer can benefit from systemic chemotherapy. Traditional platinum-based therapy has significant side effects. Oxaliplatin and docetaxel have both shown to be effective for lung cancer. The purpose of this study is to determine if oxaliplatin combined with docetaxel has a lower toxicity profile and to determine the response rate to this study drug combination.
Phase:
Phase 2
Details
Lead Sponsor:
Oncology Specialists, S.C.
Collaborator:
Sanofi-Synthelabo
Treatments:
Docetaxel
Oxaliplatin